Importer of Controlled Substances Application: Cambridge Isotope Laboratories, 60897-60898 [2018-25869]
Download as PDF
<![CDATA[
60897
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
Controlled substance
Drug code
Schedule
Remifentanil .............................................................................................................................................................
9739
II
The company plans to import the
above listed controlled substance for
research purposes.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Administration (DEA) as bulk a
manufacturer of various classes of
schedule I and II controlled substances.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[Docket No. DEA–392]
SUPPLEMENTARY INFORMATION:
Bulk Manufacturer of Controlled
Substances Registration
[FR Doc. 2018–25873 Filed 11–26–18; 8:45 am]
ACTION:
BILLING CODE 4410–09–P
Notice of registration.
The registrant listed below
has applied for and been granted
registration by the Drug Enforcement
SUMMARY:
The
company listed below applied to be
registered as bulk manufacturer of
various basic classes of controlled
substances. Information on the
previously published notice is listed in
the table below. No comments or
objections were submitted for this
notice.
Company
FR Docket
Rhodes Technologies .............................................................
83 FR 40567 ..........................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25875 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cambridge Isotope
Laboratories
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 27, 2018. Such
persons may also file a written request
for a hearing on the application on or
before December 27, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
Published
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on August
30, 2018, Cambridge Isotope
Laboratories, 50 Frontage Road,
Andover, Massachusetts 01810 applied
to be registered as an importer of the
following basic classes of controlled
substances:
amozie on DSK3GDR082PROD with NOTICES1
Controlled substance
Drug code
Tetrahydrocannabinols ............................................................................................................................................
Gamma Hydroxybutyric Acid ...................................................................................................................................
Morphine ..................................................................................................................................................................
VerDate Sep<11>2014
17:45 Nov 26, 2018
Jkt 247001
PO 00000
Frm 00077
Fmt 4703
August 15, 2018.
Sfmt 4703
E:\FR\FM\27NON1.SGM
27NON1
7370
2010
9300
Schedule
I
I
II
60898
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
The company plans to import the listed
controlled substances for analytical
research, testing and clinical trials.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25869 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Noramco Inc.
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 28, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Notice of application.
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 4,
2018, Noramco Inc., 1550 Olympic Dr.
Athens, Georgia 30601 applied to be
registered as a bulk manufacturer for the
basic classes of controlled substances:
Controlled substance
Drug code
amozie on DSK3GDR082PROD with NOTICES1
Cathinone ................................................................................................................................................................
Gamma Hydroxybutyric Acid ...................................................................................................................................
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
Codeine-N-oxide ......................................................................................................................................................
Dihydromorphine .....................................................................................................................................................
Hydromorphinol .......................................................................................................................................................
Morphine-N-oxide ....................................................................................................................................................
Amphetamine ..........................................................................................................................................................
Lisdexamfetamine ...................................................................................................................................................
Methylphenidate ......................................................................................................................................................
Nabilone ..................................................................................................................................................................
Codeine ...................................................................................................................................................................
Dihydrocodeine ........................................................................................................................................................
Oxycodone ..............................................................................................................................................................
Hydromorphone .......................................................................................................................................................
Hydrocodone ...........................................................................................................................................................
Morphine ..................................................................................................................................................................
Oripavine .................................................................................................................................................................
Thebaine ..................................................................................................................................................................
Opium tincture .........................................................................................................................................................
Oxymorphone ..........................................................................................................................................................
Noroxymorphone .....................................................................................................................................................
Alfentanil ..................................................................................................................................................................
Sufentanil .................................................................................................................................................................
Carfentanil ...............................................................................................................................................................
Tapentadol ...............................................................................................................................................................
Fentanyl ...................................................................................................................................................................
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) and reference standards for
distribution to their customers.
In reference to drug codes 7360
(marihuana) and 7370
(tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25874 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
Jkt 247001
The registrant listed below
has applied for and has been granted
registration by the Drug Enforcement
Administration (DEA) as an importer of
schedule I or II controlled substances.
The
company listed below applied to be
registered as an importer of various
basic classes of controlled substances.
Information on the previously published
notice is listed in the table below. No
comments or objections were submitted
and no requests for a hearing were
submitted for this notice.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
ACTION:
17:45 Nov 26, 2018
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
SUMMARY:
Importer of Controlled Substances
Registration
VerDate Sep<11>2014
1235
2010
7360
7370
9053
9145
9301
9307
1100
1205
1724
7379
9050
9120
9143
9150
9193
9300
9330
9333
9630
9652
9668
9737
9740
9743
9780
9801
Schedule
PO 00000
Notice of registration.
Frm 00078
Fmt 4703
Sfmt 4703
E:\FR\FM\27NON1.SGM
27NON1
]]>Agencies
[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Pages 60897-60898]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25869]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Cambridge Isotope
Laboratories
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before December 27, 2018.
Such persons may also file a written request for a hearing on the
application on or before December 27, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on August
30, 2018, Cambridge Isotope Laboratories, 50 Frontage Road, Andover,
Massachusetts 01810 applied to be registered as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols................... 7370 I
Gamma Hydroxybutyric Acid............... 2010 I
Morphine................................ 9300 II
------------------------------------------------------------------------
[[Page 60898]]
The company plans to import the listed controlled substances for
analytical research, testing and clinical trials.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-25869 Filed 11-26-18; 8:45 am]
BILLING CODE 4410-09-P
